Research

LIke ThisLIke ThisLIke This

Andrew  Place, MD, PhD

Research Center:
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Department:
Medicine Research
Division
Hematology/Oncology Research
Hospital Title:
Staff Physician/Assistant in Medicine
Academic Title:
Instructor in Pediatrics, Harvard Medical School
Research Focus Area:
LeukemiaLymphomaRelapsed Acute Lymphoblastic Leukemia
Contact:
617-632-2313
Contact Via Email
Send an email to SendYour Name*Your Email Address*Subject*Comments*

Research Overview

Over the last several decades, there have been dramatic improvements in the treatment of the most common types of pediatric cancers. However, despite these successes, relapsed or refractory leukemia carry a dismal prognosis. For example, more children will succumb to relapsed acute lymphoblastic leukemia that any other type of pediatric malignancy. It is paramount that novel agents and treatment strategies are developed for these cancers that improve outcomes while limiting both the acute and long-term toxicities of therapy.

In order to achieve these goals, we are developing a robust translational program supported by our own world-class basic science laboratories, extensive collection of clinical samples and well-known expertise in clinical trial design and administration. By encouraging collaborations within academia and industry we foster pre-clinical evaluation of the most compelling novel therapies as a mechanism to stream line their introduction into early phase clinical trials.

About Andrew Place

Dr. Place received his PhD in Pharmacology and Toxicology from Dartmouth College in 2004 and his MD from the Dartmouth Medical School in 2006. He completed his pediatric residency training in the Boston Combined Residency Program at Boston Children’s Hospital and Boston Medical Center. He subsequently completed a fellowship in pediatric hematology-oncology at Boston Children’s Hospital and the Dana-Farber Cancer Institute. In 2012, he became an attending physician in Pediatric Oncology at the Dana-Farber/Children’s Hospital Cancer Center, where he currently participates in the development of early phase clinical trials in the Pediatric Hematologic Malignancy Service.

Publications

Publications powered by Harvard Catalyst Profiles
  1. Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerriero JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, Hilsenbeck S, Schiff R, Osborne KC, Letai A, Polyak K. Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Res. 2016 Sep 26.
  2. Place AE, Frederick NN, Sallan SE. Therapeutic approaches to haematological malignancies in adolescents and young adults. Br J Haematol. 2014 Jan; 164(1):3-14.
  3. Janeway KA, Place AE, Kieran MW, Harris MH. Future of clinical genomics in pediatric oncology. J Clin Oncol. 2013 May 20; 31(15):1893-903.
  4. Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res. 2011; 13(6):227.
  5. Place AE. Pre-Clinical Evaluation of the Novel Synthetic Triterpenoid CDDO-Imidazolide. 2004.
  6. Karen Liby, Andrew E. Place, Nanjoo Suh, Renee Risingsong, Charlotte Williams, Nathalie Hill-Kapturczak, Anupam Agarwal, Tadashi Honda, Gordon Gribble and Michael B. Sporn . The synthetic triterpenoid, CDDO-Imidazolide, activates heme oxygenase-1 and other Nrf2-responsive genes in human leukemia cells . Proceedings of the 95th Annual Meeting of the American Association for Cancer Research. 2004; 318.
  7. Place AE, Suh N, Williams CR, Risingsong R, Honda T, Honda Y, Gribble GW, Leesnitzer LM, Stimmel JB, Willson TM, Rosen E, Sporn MB. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res. 2003 Jul; 9(7):2798-806.
  8. Suh N, Roberts AB, Birkey Reffey S, Miyazono K, Itoh S, ten Dijke P, Heiss EH, Place AE, Risingsong R, Williams CR, Honda T, Gribble GW, Sporn MB. Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. Cancer Res. 2003 Mar 15; 63(6):1371-6.
  9. Place, A. E., Suh, N., Rendi, M., Williams, C., Risingsong, R., Honda, T., Gribble, G., and Sporn, M. B. Pre-Clinical Evaluation of Synthetic Triterpenoids for Prevention and Treatment of Cancer. Proceeding of the 1st Annual Meeting of Frontiers in Cancer Prevention Research. 2003.
  10. Honda T, Honda Y, Favaloro FG, Gribble GW, Suh N, Place AE, Rendi MH, Sporn MB. A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg Med Chem Lett. 2002 Apr 8; 12(7):1027-30.
  11. Show all
  12. Place, A.E., Suh, N., Rendi, M., Honda, T., Gribble, G., and Sporn, M.B. Synthetic Triterpenoids Induce Differentiation of Human Leukemia Cells and Reduce Tumor Burden in Murine Cancer Models. Proceedings of the 93th Annual Meeting of the American Association for Cancer Research. 2002.
  13. Ito Y, Pandey P, Place A, Sporn MB, Gribble GW, Honda T, Kharbanda S, Kufe D. The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Differ. 2000 May; 11(5):261-7.
  14. Pandey P, Avraham S, Place A, Kumar V, Majumder PK, Cheng K, Nakazawa A, Saxena S, Kharbanda S. Bcl-xL blocks activation of related adhesion focal tyrosine kinase/proline-rich tyrosine kinase 2 and stress-activated protein kinase/c-Jun N-terminal protein kinase in the cellular response to methylmethane sulfonate. J Biol Chem. 1999 Mar 26; 274(13):8618-23.
  15. Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, Hickey WF, Maue RA, Place AE, Porter DM, Spinella MJ, Williams CR, Wu G, Dannenberg AJ, Flanders KC, Letterio JJ, Mangelsdorf DJ, Nathan CF, Nguyen L, Porter WW, Ren RF, Roberts AB, Roche NS, Subbaramaiah K, Sporn MB. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res. 1999 Jan 15; 59(2):336-41.
  16. Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, Williams CR, Royce DB, Honda T, Honda Y, Gribble GW, Hill-Kapturczak N, Agarwal A, Sporn MB. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 2005 Jun 1; 65(11):4789-98.
  17. Pandey P, Avraham S, Kumar S, Nakazawa A, Place A, Ghanem L, Rana A, Kumar V, Majumder PK, Avraham H, Davis RJ, Kharbanda S. Activation of p38 mitogen-activated protein kinase by PYK2/related adhesion focal tyrosine kinase-dependent mechanism. J Biol Chem. 1999 Apr 9; 274(15):10140-4.
  18. Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec; 16(16):1677-90.
  19. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekoffer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LaBoeuf N, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 Apr 11; 29(4):574-86.
LIke ThisLIke ThisLIke This

RELATED RESEARCH CENTER

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

Dana-Farber/Boston Children's Cancer and Blood Disorders Center is one of the top research centers in the world for pediatric cancers and blood diseases. It brings together laboratory scientists and clinical researchers from Dana-Farber Cancer Institute and Boston Children’s Hospital in a single program. We investigate pediatric cancers and non-malignant blood disorders from every angle—from examining cells under the microscope to tracking the effectiveness of current drug regimens using the most advanced molecular methods—so that we can create better treatments for children seen here and around the world.

Learn more
Close